Publication

Adenosine A(2A) Receptor Antagonists as Positron Emission Tomography (PET) Tracers

Khanapur, S., van Waarde, A., Ishiwata, K., Leenders, K. L., Dierckx, R. A. J. O. & Elsinga, P. H., Jan-2014, In : CURRENT MEDICINAL CHEMISTRY. 21, 3, p. 312-328 17 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Khanapur, S., van Waarde, A., Ishiwata, K., Leenders, K. L., Dierckx, R. A. J. O., & Elsinga, P. H. (2014). Adenosine A(2A) Receptor Antagonists as Positron Emission Tomography (PET) Tracers. CURRENT MEDICINAL CHEMISTRY, 21(3), 312-328.

Author

Khanapur, S. ; van Waarde, A. ; Ishiwata, K. ; Leenders, K. L. ; Dierckx, R. A. J. O. ; Elsinga, P. H. / Adenosine A(2A) Receptor Antagonists as Positron Emission Tomography (PET) Tracers. In: CURRENT MEDICINAL CHEMISTRY. 2014 ; Vol. 21, No. 3. pp. 312-328.

Harvard

Khanapur, S, van Waarde, A, Ishiwata, K, Leenders, KL, Dierckx, RAJO & Elsinga, PH 2014, 'Adenosine A(2A) Receptor Antagonists as Positron Emission Tomography (PET) Tracers', CURRENT MEDICINAL CHEMISTRY, vol. 21, no. 3, pp. 312-328.

Standard

Adenosine A(2A) Receptor Antagonists as Positron Emission Tomography (PET) Tracers. / Khanapur, S.; van Waarde, A.; Ishiwata, K.; Leenders, K. L.; Dierckx, R. A. J. O.; Elsinga, P. H.

In: CURRENT MEDICINAL CHEMISTRY, Vol. 21, No. 3, 01.2014, p. 312-328.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Khanapur S, van Waarde A, Ishiwata K, Leenders KL, Dierckx RAJO, Elsinga PH. Adenosine A(2A) Receptor Antagonists as Positron Emission Tomography (PET) Tracers. CURRENT MEDICINAL CHEMISTRY. 2014 Jan;21(3):312-328.


BibTeX

@article{edd9931ef17e47e9a3c51d3b92220680,
title = "Adenosine A(2A) Receptor Antagonists as Positron Emission Tomography (PET) Tracers",
abstract = "The adenosine A(2A) receptor (A(2A)R) is highly concentrated in the striatum, and a therapeutic target for Parkinson's disorder (PD) and Huntington's disease. High affinity and selective radiolabeled A(2A)R antagonists can be important research and diagnostic tools for PD. Positron Emission Tomography (PET) can play an important role by measuring radiolabeled A(2A) antagonists non-invasively in the brain. However, till date no complete review on A(2A)R PET ligands is available. The present article has been therefore focused on available PET tracers for A(2A)R and their detailed biological evaluation in rodents, nonhuman primates and humans. Drug design and development by molecular modeling including new lead structures that are potential candidates for radiolabeling and mapping of cerebral A(2A)Rs is discussed in the present article. A brief overview of functions of adenosine in health and disease, including the relevance of A(2A)R for PD has also been presented.",
keywords = "Adenosine A(2A) receptor, Parkinson's disorder, positron emission tomography (PET), xanthine ligands, nonxanthine, ligands, SCH442416, TMSX, 6-OHDA PD model, CENTRAL-NERVOUS-SYSTEM, MOVEMENT-DISORDER SOCIETY, JOINT TASK-FORCE, PARKINSONS-DISEASE, RAT-BRAIN, THERAPEUTIC MANAGEMENT, PIPERAZINE DERIVATIVES, NEUROLOGICAL SOCIETIES, MEDICINAL CHEMISTRY, EUROPEAN FEDERATION",
author = "S. Khanapur and {van Waarde}, A. and K. Ishiwata and Leenders, {K. L.} and Dierckx, {R. A. J. O.} and Elsinga, {P. H.}",
year = "2014",
month = "1",
language = "English",
volume = "21",
pages = "312--328",
journal = "CURRENT MEDICINAL CHEMISTRY",
issn = "0929-8673",
publisher = "BENTHAM SCIENCE PUBL LTD",
number = "3",

}

RIS

TY - JOUR

T1 - Adenosine A(2A) Receptor Antagonists as Positron Emission Tomography (PET) Tracers

AU - Khanapur, S.

AU - van Waarde, A.

AU - Ishiwata, K.

AU - Leenders, K. L.

AU - Dierckx, R. A. J. O.

AU - Elsinga, P. H.

PY - 2014/1

Y1 - 2014/1

N2 - The adenosine A(2A) receptor (A(2A)R) is highly concentrated in the striatum, and a therapeutic target for Parkinson's disorder (PD) and Huntington's disease. High affinity and selective radiolabeled A(2A)R antagonists can be important research and diagnostic tools for PD. Positron Emission Tomography (PET) can play an important role by measuring radiolabeled A(2A) antagonists non-invasively in the brain. However, till date no complete review on A(2A)R PET ligands is available. The present article has been therefore focused on available PET tracers for A(2A)R and their detailed biological evaluation in rodents, nonhuman primates and humans. Drug design and development by molecular modeling including new lead structures that are potential candidates for radiolabeling and mapping of cerebral A(2A)Rs is discussed in the present article. A brief overview of functions of adenosine in health and disease, including the relevance of A(2A)R for PD has also been presented.

AB - The adenosine A(2A) receptor (A(2A)R) is highly concentrated in the striatum, and a therapeutic target for Parkinson's disorder (PD) and Huntington's disease. High affinity and selective radiolabeled A(2A)R antagonists can be important research and diagnostic tools for PD. Positron Emission Tomography (PET) can play an important role by measuring radiolabeled A(2A) antagonists non-invasively in the brain. However, till date no complete review on A(2A)R PET ligands is available. The present article has been therefore focused on available PET tracers for A(2A)R and their detailed biological evaluation in rodents, nonhuman primates and humans. Drug design and development by molecular modeling including new lead structures that are potential candidates for radiolabeling and mapping of cerebral A(2A)Rs is discussed in the present article. A brief overview of functions of adenosine in health and disease, including the relevance of A(2A)R for PD has also been presented.

KW - Adenosine A(2A) receptor

KW - Parkinson's disorder

KW - positron emission tomography (PET)

KW - xanthine ligands

KW - nonxanthine

KW - ligands

KW - SCH442416

KW - TMSX

KW - 6-OHDA PD model

KW - CENTRAL-NERVOUS-SYSTEM

KW - MOVEMENT-DISORDER SOCIETY

KW - JOINT TASK-FORCE

KW - PARKINSONS-DISEASE

KW - RAT-BRAIN

KW - THERAPEUTIC MANAGEMENT

KW - PIPERAZINE DERIVATIVES

KW - NEUROLOGICAL SOCIETIES

KW - MEDICINAL CHEMISTRY

KW - EUROPEAN FEDERATION

M3 - Article

VL - 21

SP - 312

EP - 328

JO - CURRENT MEDICINAL CHEMISTRY

JF - CURRENT MEDICINAL CHEMISTRY

SN - 0929-8673

IS - 3

ER -

ID: 13706062